In summary, in another study [88] on HNSCC in which a reverse-phase protein array technique was used, the authors revealed that cancer cell lines derived from HNSCC with PIK3CA mutations were sensitive to PI3K pathway inhibitors, whereas amplification status did not predict sensitivity. The gene discussed is PIK3CG; the disease is cancer.